All differentiation markers (CYP3A4, HNF4α and albumin) in infigratinib‐treated FGFR‐dependent tumours were significantly increased compared with their levels in vehicle‐treated tumours (Figure 2A). The gene discussed is ALB; the disease is neoplasm.